Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 131

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 131
---
3, NewGenIvf had US$457,740 and US$54,104, respectively, in cash and cash equivalents. NewGenIvf had working
capital (defined as total current assets deducted by total current liabilities) of a surplus of $452,391 and US$79,000, respectively,
as of December 31, 2024 and 2023.

As of December 31, 2024, NewGenIvf
owed US$154,453 to shareholders. Nevertheless, NewGenIvf is able to generate sufficient cash flow from its business operations and financing
activities to operate and grow its business.

NewGenIvf continually seeks
to monetize from positive cash flow contracts and increase revenue from its operating activities. NewGenIvf monitors its current and expected
liquidity requirements to help ensure that it maintains sufficient cash balances to meet its existing and reasonably likely long-term
liquidity needs.

NewGenIvf intends to finance
its future working capital requirements and capital expenditures from cash generated from operating activities, in addition to funds raised
from financing activities. NewGenIvf may, however, require additional cash due to changing business conditions or other future developments,
including any investments or acquisitions it may decide to pursue. If its existing cash is insufficient to meet its requirements, NewGenIvf
may seek to issue debt or equity securities or obtain additional credit facilities. Financing may be unavailable in the amounts NewGenIvf
needs or on terms acceptable to it, if at all. Issuance of additional equity securities, including convertible debt securities, would
dilute NewGenIvf’s earnings per share. The incurrence of debt would divert cash for working capital and capital expenditures to
service debt obligations and could result in operating and financial covenants that restrict NewGenIvf’s operations and its ability
to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing as required, its business operations
and prospects may suffer. Please see “Risk Factors — Risks Relating to NewGenIvf’s Business and Industry — NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may be materially and adversely affected.”

The following table presents
NewGenIvf’s selected consolidated cash flow data for the periods indicated.

|                                                                     |     | For the Year ended 
 December 31,       
 2024